I-Mab Says Selling Shareholders to Offer 3.3 Million ADSs
06:54 AM EST, 02/08/2021 (MT Newswires) -- I-Mab (IMAB), a clinical stage biopharmaceutical company, on Friday launched a registered underwritten public offering of 3,283,950 American Depositary Shares by selling shareholders.
Each 10 ADSs represent 23 ordinary shares of the company. I-Mab will not receive any proceeds from the public offering.
The selling shareholders granted underwriters an option to purchase up to an additional 492,590 ADSs.
Price: 62.00, Change: -0.80, Percent Change: -1.27